How much is stem cell therapy? According to analysis by BioInformant, the cost of stem cell therapy ranges from less than $5,000 for simple procedures to $25,000 or more for complex ones. In general, stem cell treatment procedures are paid out-of-pocket by patients, because they are not covered by medical insurance. The cost of platelet rich therapy (PRP), which can be used separately or in conjunction with stem cell therapy, is typically $500-700, but may be as high as $2,000 at some locations. [Read more…]
A Multi-Version Medicinal Technology System, Part II
A New Generation of MSC Applications
With scientific results dismally challenging to replicate properly across disciplines, scientists, technologists, or investors with intact survival instincts cannot be naïve. No matter how gruff it sounds, a healthy respect for due diligence and fiduciary responsibility demands that good people ask, “Where’s the beef!?” at any time. In Part I of this article, we first heard about “MSC 2.0,” 17 which is the second generation of mesenchymal stem/stromal cell (MSC) cellular technology. Like T cells, MSCs are a raw primary cellular source that irrigates multiple branches of downstream clinical applications that intermingle with other technologies. Although one potentially promising use of “v2.0” involves cell-cultured and/or cruelty-free meat (aka “clean meat”), 76 we aim to inform you here that MSC 2.0 now supports other—more near-term—ventures of direct benefit to human health. [Read more…]
MSCs: A Multi-Version Medicinal Technology System, Part I
The Most Interesting Things Take Time
The world’s first approved product from monoclonal antibody technology was Muromonab-CD3 (Orthoclone OKT3), launched in 1986. It’s a prime example of “mAb version 1.0,” unleashed before a wave of newer, more manufacturable and better engineered products would begin to enter the market in the late-90s. Later molecular and process iterations based on “mAb 1.0” would take several decades to finally ramify into diverse platforms such as CAR-T, Bi-specific T-cell engagers (BiTEs), diagnostics, and biosensors. As a cellular technology platform, mesenchymal stem/stromal cells (MSCs) are proceeding with a story of convergent evolution. [Read more…]
iPSC Market Leaders and their Business Models
Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. [Read more…]
Induced Pluripotent Stem Cell (iPS Cell) Applications in 2024
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 196
- Next Page »